BiomX Inc.

BiomX Inc. (Nasdaq: PHGE) is a clinical-stage biopharmaceutical company that completed its business combination with Chardan Healthcare Acquisitions Corp., sponsored by Chardan Capital Markets, in October 2019. The company, which operates in the phage therapy segment of the broader biopharmaceuticals sector, develops bacteriophage-based therapies targeting chronic diseases driven by harmful bacteria. BiomX has continued to advance its pipeline through clinical trials following the de-SPAC transaction and filed an 8-K with the Securities and Exchange Commission on April 10, 2026. For comprehensive filings history, pipeline milestones, and SPAC deal metrics on BiomX and hundreds of other transactions, sign up for full data access at SpacDesk.